Patents by Inventor Hank F. Kung

Hank F. Kung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RADIOACTIVELY LABELED LIGAND FOR FIBROBLAST ACTIVATION PROTEIN-ALPHA IMAGING AGENT AND PREPARATION METHOD THEREFOR
    Publication number: 20240139350
    Abstract: A radioactively labeled ligand for a fibroblast activation protein-alpha imaging agent and a preparation method therefor are provided. The radioactively labeled ligand for the fibroblast activation protein-alpha imaging agent has structural formal (I). The compound has a good 68Ga labeling property, a high stability and a good affinity for FAP tumors. The radioactively labeled ligand for 68Ga-labeled FAPi can be used as a tumor positron imaging agent.
    Type: Application
    Filed: February 1, 2021
    Publication date: May 2, 2024
    Inventors: Hank F KUNG, Zhihao ZHA, Karl PLOESSL, Seok Rye CHOI, David ALEXOFF
  • PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS DIAGNOSTIC AND RADIONUCLIDE THERAPEUTIC AGENTS
    Publication number: 20220125959
    Abstract: The present disclosure relates to compounds according to Formula I. These compounds display very good binding affinities to the PSMA binding sites. They comprise a radioactive isotope or a chelating moiety that can be labeled with a radioactive metal such as [68Ga]or [177Lu]. The present disclosure also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or a complex thereof, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 27, 2020
    Publication date: April 28, 2022
    Inventors: Hank F. KUNG, Zhihao ZHA, Karl PLOESSL, Seok Rye CHOI
  • NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION
    Publication number: 20210346526
    Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 26, 2021
    Publication date: November 11, 2021
    Inventors: Zehui WU, Zhihao ZHA, Futao LIU, Karl PLOESSL, Seok Rye CHOI, Hank F. KUNG
  • Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application
    Patent number: 11071794
    Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: July 27, 2021
    Assignee: Five Eleven Pharma Inc.
    Inventors: Zehui Wu, Zhihao Zha, Futao Liu, Karl Ploessl, Seok Rye Choi, Hank F. Kung
  • Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application
    Patent number: 10912849
    Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: February 9, 2021
    Assignee: FIVE ELEVEN PHARMA INC.
    Inventors: Zehui Wu, Zhihao Zha, Futao Liu, Karl Ploessl, Seok Rye Choi, Hank F. Kung
  • NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION
    Publication number: 20200230263
    Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 19, 2020
    Publication date: July 23, 2020
    Applicant: Five Eleven Pharma Inc.
    Inventors: Zehui WU, Zhihao ZHA, Futao LIU, Karl PLOESSL, Seok Rye CHOI, Hank F. KUNG
  • Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
    Patent number: 10688200
    Abstract: The present invention relates to compounds according to Formula I and Formula IV. These compounds display very good binding affinities to the PSMA binding sites. They can be labeled with [68Ga]GaCl3 with high yields and excellent radiochemical purity. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula IV, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: June 23, 2020
    Assignee: FIVE ELEVEN PHARMA INC.
    Inventors: Hank F. Kung, Karl Ploessl, Seok Rye Choi, Zhihao Zha, Zehui Wu
  • HBED-bisphosphonates, radiometal conjugates and their use as theranostic agents
    Patent number: 10253052
    Abstract: The present invention relates to compounds according to Formula I or Formula II, which are potential bone imaging agents. Certain compounds labeled with 68Ga displayed excellent bone uptake and retention. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula II or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: April 9, 2019
    Assignee: Five Eleven Pharma Inc.
    Inventors: Hank F. Kung, Zehui Wu, Seok Rye Choi, Karl Plössl, Zhihao Zha
  • NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION
    Publication number: 20180344882
    Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 31, 2018
    Publication date: December 6, 2018
    Inventors: Zehui WU, Zhihao ZHA, Futao LIU, Karl PLOESSL, Seok Rye CHOI, Hank F. KUNG
  • UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY
    Publication number: 20170189568
    Abstract: The present invention relates to compounds according to Formula I and Formula IV. These compounds display very good binding affinities to the PSMA binding sites. They can be labeled with [68Ga]GaCl3 with high yields and excellent radiochemical purity. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula IV, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 20, 2016
    Publication date: July 6, 2017
    Inventors: Hank F. KUNG, Karl PLOESSL, Seok Rye CHOI, Zhihao ZHA, Zehui WU
  • HBED-Bisphosphonates, Radiometal Conjugates and Their Use as Theranostic Agents
    Publication number: 20170022224
    Abstract: The present invention relates to compounds according to Formula I or Formula II, which are potential bone imaging agents. Certain compounds labeled with 68Ga displayed excellent bone uptake and retention. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula II or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 6, 2016
    Publication date: January 26, 2017
    Applicant: Five Eleven Pharma Inc.
    Inventors: Hank F. KUNG, Zehui Wu, Seok Rye Choi, Karl PLÖSSL, Zhihao Zha
  • Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
    Patent number: 8840866
    Abstract: This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: September 23, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Hank F. Kung, Mei-Ping Kung
  • Single diastereomers of 4-fluoroglutamine and methods of their preparation and use
    Patent number: 8747809
    Abstract: The present invention is directed single diasteromers of 4-fluoroglutamine having a diastereomeric excess of at least 80%. Methods of preparing the single diastereomers are also described, as well as methods of using the single diastereomers of radiolabeled 4-fluoroglutamine as imaging agent is also described.
    Type: Grant
    Filed: August 13, 2010
    Date of Patent: June 10, 2014
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Hank F. Kung, Craig B. Thompson, Wenchao Qu, Karl Ploessl
  • Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents
    Patent number: 8562949
    Abstract: This invention relates to a method of imaging vesicular monoamine transporters and to labeled compounds and pharmaceutical compositions thereof, and methods of making labeled compounds useful in imaging vesicular monoamine transporters. This invention also relates to compounds, and methods of monitoring progression of a disease related to vesicular monoamine transporters.
    Type: Grant
    Filed: May 2, 2007
    Date of Patent: October 22, 2013
    Assignees: The Trustees of the University of Pennsylvania, The Regents of the University of Michigan, Avid Radiopharmaceuticals, Inc.
    Inventors: Hank F. Kung, Mei-Ping Kung, Michael Kilbourn, Daniel M. Skovronsky
  • Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
    Patent number: 8506929
    Abstract: This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
    Type: Grant
    Filed: August 5, 2008
    Date of Patent: August 13, 2013
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Hank F. Kung, Mei-Ping Kung
  • Stilbene derivatives and their use for binding and imaging amyloid plaques
    Patent number: 8465726
    Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: June 18, 2013
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang
  • STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES
    Publication number: 20130129624
    Abstract: This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
    Type: Application
    Filed: January 7, 2013
    Publication date: May 23, 2013
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Hank F. Kung, Mei-Ping Kung
  • SINGLE DIASTEREOMERS OF 4-FLUOROGLUTAMINE AND METHODS OF THEIR PREPARATION AND USE
    Publication number: 20120288444
    Abstract: The present invention is directed single diasteromers of 4-fluoroglutamine having a diastereomeric excess of at least 80%. Methods of preparing the single diastereomers are also described, as well as methods of using the single diastereomers of radiolabeled 4-fluoroglutamine as imaging agent is also described.
    Type: Application
    Filed: August 13, 2010
    Publication date: November 15, 2012
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Hank F. Kung, Craig B. Thompson, Wenchao Qu, Karl Ploessl
  • Amyloid plaque aggregation inhibitors and diagnostic imaging agents
    Patent number: RE44338
    Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: July 2, 2013
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang, Virginia M. Y. Lee, John Q. Trojanowski, Daniel M. Skovronsky
  • Amyloid plaque aggregation inhibitors and diagnostic imaging agents
    Patent number: RE44354
    Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form-amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: July 9, 2013
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang, Virginia M. Y. Lee, John Q. Trojanowski, Daniel M. Skovronsky